Methods of detecting and assessing estrogenic compounds have been previously described (5) and critically evaluated (6) . Biotransformation and consequent alteration of hormonal activity by test systems is an important consideration because phenolic metabolites produced by the action of cytochrome P450 enzymes can be more potent than the parent compounds (7, 8) . Clearly, although such metabolic effects are intrinsic to in vivo models, they may not be so readily reflected by in vitro test systems. Estrogen-sensitive human breast cancer cells, such as MCF-7 cells, express the human estrogen receptor and have been used to develop E-screen tests for chemicals (9) and contaminants in animal feeds (10) . Uterotrophic assays such as the classical mouse uterine weight bioassay (11) have limitations (6) , but are still preferred methods for many investigators (12) . Uterotrophic assays also offer the potential to combine biochemical and histological analysis of estrogen-mediated events and further adaptation to measure antiuterotrophic activity (13) .
The use of receptors linked to reporter genes in transformed cellular systems to detect biologically active xenobiotics has been proposed as a strategy to define chemicals by their functional properties (2) .
This approach facilitates detection of not only receptor ligand binding but also response element occupancy and gene activation. The recombinant yeast cells used in the present report have recently been used in an ultrasensitive RCBA for the determination of prepubertal plasma estrogens (14) . These cells contain an expression plasmid that indudes the CUPI metallothionein promoter fused to the human estrogen receptor cDNA and a reporter plasmid which contains two copies of the frog vitellogenin estrogen response element upstream of the yeast iso-i-cytochrome c promoter fused to the structural gene for P-galactosidase.
Similar recombinant yeast cell systems have been used for the detection of xenoestrogens (15, 16) and various estrogen receptor studies (17) (18) (19) . The particular advantage of the transformed yeast cell line approach is that the cells are robust and substrate auxotrophy may be used to continuously select for estrogen sensitivity. Moreover, expression of human estrogen receptor and ability to automate suggest that these yeast cells have much to offer the analyst requiring an in vitro screening assay that affords some reflection of potential estrogenic activity in humans.
In the present study, bioassays were evaluated by comparison of the potency of test compounds relative to 17p-estradiol (E2) since this natural estrogen is the most commonly accepted positive control used in such in vivo and in vitro assays (20, 21 
RCBA ofestrogens. Procedures that were followed were similar to those described previously (14) . Briefly, a small colony of ( (23) . 9MCF-7 cell proliferation assay; data from Welshons et al. (10) . fHeLa cell cotransfection assay; data from Miksicek (20) . gRelative proliferative potency in E-screen assay; data from Sonnenschien, et al. (24) . hCompetitive binding radio-receptor assay; data from Korach et al. (8) . 'Competitive binding radioreceptor assay-progesterone receptor induction; data from Krishnan et al. (25) . Uterotrophic assay. Prepubertal 18-dayold CFLP female mice (Harlan U.K. Ltd., Huntingdon, U.K.) were injected subcutaneously with 0.1 ml test compound dissolved in corn oil at the doses shown in Table 2 , on three consecutive days, essentially as described by Rubin et al. (11) . In each assay, five concentrations of E2 (calibrant) and three concentrations of test compound were injected using seven animals per dose. Mice were sacrificed on the fourth day and the weights of the animal and uteri recorded; a sample of vagina was fixed in phosphate buffered saline containing 1% formaldehyde and processed for routine histological evaluation. Results are expressed as the mean ratio of uterine weight to body weight. The relative potency of test compounds was determined by interpolation from calibration curves of the molar dose of E2 and test compounds that provided similar increases in ratios of uterine wt/body wt x 100. Care and treatment of the mice was in accordance with the Animals (Scientific Procedures) Act 1986 of the United Kingdom and supervised by a veterinary surgeon.
Human breast cancer cell proliferation assay. MCF-7 human breast cancer cells were maintained in Eagles minimal essential medium (EMEM) supplemented with 5% E2 dose (mol) Figure 1 . 173-Estradiol (E2) calibration curves derived from the recombinant yeast cell bioassay (RCBA; n = 8), the MCF-7 human breast cancer cell proliferation assay (n = 4), and the prepubertal mouse uterotrophic assay (n = 7). Induction of galactosidase activity (RCBA), increase in cell number (MCF-7 cell proliferation assay), and uterine weight (prepubertal mouse uterine weight assay) were normalized to percentage response and are plotted against the total number of moles of E2 added to the test system. Error bars represent ± 1 standard deviation. Figure 2 and Table 2 , respectively. Potential interference of estrogenic residues leaching from the plastic microwells in the RCBA was determined by comparing E2 calibration curves prepared in untreated and washed ( Table 1 . Effect ofE2 + 4-hydroxytamoxifen in RCBA. The effect of 4-hydroxytamoxifen (10-9-10-5 M) and E2 (10-13-10-7 M), both singly and in combination, on P-glactosidase activity induction is shown in Figure 3 . p- with E2 alone. 4-Hydroxytamoxifen displayed agonist activity when tested in isolation; as a result, 3-galactosidase activity was significantly (p>0.05) elevated by relatively high doses of4-hydroxytamoxifen when tested with a low dose of E2 (e.g., 10-13 M E2 + 10-9_10-5 M 4-hydroxytamoxifen) when compared with E2 alone (Fig. 3) .
Determination of relative estrogenic potency using the mouse uterine weight assay. The uterotrophic effect and relative estrogenic potencies of E2, diethylstibestrol, 4-nonylphenol, 4-octylphenol, coumestrol, oa-zearalanol, bisphenol A, dibutylphthalates, and benzylbutylphthalates are shown in Table 2 . 4-Nonylphenol, coumestrol, at-zearalanol, and diethylstilbestrol significantly (p<0.05) increased uterine weight at the doses shown. After the first injection of the highest doses of 4-nonylphenol and bisphenol A, symptoms of acute toxicity were evident and, as a consequence, these mice were immediately withdrawn from the study and euthanized.
Xenobiotic biotransformation. Analysis of incubation medium revealed no evidence of xenobiotic metabolism following incubation of yeast cells with E2, coumestrol, dibutylphthalate, diethylstilbestrol, testosterone, and 4- nonylphenol. In the case of a-zearalanol, a single metabolite (5% of total) was detected in the medium after 18 hr (data not shown).
Discussion
High sensitivity is an important requirement for screening assays to enable detection of compounds of low potency that may be of Volume 105, Number 7, July 1997 * Environmental Health Perspectives
Articles -Recombinant yeast cell estrogen screenin_ bioassay biological significance through chronic exposure and/or high abundance in the environment. The effect of E2 on MCF-7 cell proliferation and uterotrophic activity found in the present study was similar to that observed in previous reports (10, 11, 29 (24) . Uterotrophic bioassays also offer the simultaneous measurement of other markers of estrogen action including vaginal and uterine cell proliferation, which may be used to provide definitive confirmation of estrogenic activity (32) . One potential disadvantage of MCF-7 cells is that under certain conditions they may also express receptors for other classes of steroids (33) , and other hormones including progestagens have been shown to increase breast cancer cell proliferation (34) . Similarly, under certain circumstances uterotrophic assays are limited in selectivity for estrogens by sensitivity to androgens and progestagens (6) . For these reasons, expression of single class of steroid receptor, as in the RCBA system, is highly desirable since this provides a system with appropriate sensitivity and specificity to a single class of hormone. Moreover, the genetic simplicity of yeast cells separates estrogen receptor signaling from the confounding affects of other signaling pathways in the cell.
Evaluation of the relative estrogenic potency of steroids from different hormone dasses is necessary to demonstrate and establish assay selectivity for estrogens. This important element of assay validation also provides a reference scale for estrogenic activity found with the RCBA relative to compounds generally accepted to be either estrogens or without estrogenic activity. Many of the compounds tested with the recombinant yeast cell bioassay did not induce f3-galactosidase activity to the same extent as E2. Similar observations have been made with the Escreen breast cancer cell proliferation assay and were interpreted as indicating that the xenobiotics tested were partial agonists (24) . Evaluation of estrogenic activity with the RCBA in terms of relative potency alone can be misleading because several androgens (e.g., testosterone) have estrogenic potencies of a similar order to those of, for instance, the alkylphenols. Consideration must also be given to the relative inductive efficiency of Pgalactosidase activity by test compounds. In this regard androgens were much weaker estrogens than alkylphenols. Although androgens have uterotrophic (6) and mitogenic activity (35) at pharmacological doses in vivo, they are unlikely to be of physiological significance as estrogens because endogenous concentrations are several orders of magnitude less than used in such assays. A slight response to testosterone has been reported with a similar yeast screen for estrogens (15); indeed, the potency of testosterone found with the RCBA was an order of magnitude lower than that found with a competitive binding radioreceptor assay (22) . Synthetic estrogens including 17a-ethynylestradiol and the stilbenes were among the most potent estrogens tested comparable with E2. This contrasts with the relative estrogenic potency of most of the phytoestrogens and environmental pollutants, which were several orders of magnitude less potent than E2. Table  1 ) both within and between laboratories according to the particular assay used (20, 39) . Both the RCBA and mouse uterotrophic assay indicate that 4-nonylphenol is a more potent estrogen than 4- octylphenol, contrary to other reports (24, 40) , although the potency of 4-nonylphenol obtained with the RCBA was very similar to the E-screen (24 (19, 20) and breast cancer cell proliferation assays (10, 24) are typically sensitive to E2 at concentrations of 1 pM (Table 3) .
4-Hydroxytamoxifen is a metabolite of tamoxifen and a potent antiestrogen (28) . Although the RCBA demonstrates the ability of 4-hydroxytamoxifen to significantly inhibit E2-induced P-galactosidase activity, the response was only weak. The incomplete suppression of E2-induced ,-galactosidase activity observed may be due to the intrinsic estrogenicity of certain triarylethlyene antiestrogens like tamoxifen (41) . Given the relatively poor response to the potent antiestrogen 4-hydroxytamoxifen, it is anticipated that this system would not have sufficient sensitivity to detect weaker antiestrogens. More significant inhibition of E2-induced activity by triarylethylene antiestrogens has been demonstrated in reporter gene assays in mammalian cells (19, 20, 40) and breast cancer cell proliferation assays (42) . A yeast cell system similar to the RCBA (18) was sensitive to the estrogenic but not antiestrogenic activity of tamoxifen. Thus, these data indicate the need for further adjustment of either the RCBA assay conditions or to the plasmids that confer such extreme sensitivity to estrogens to provide more sensitive detection of antiestrogenic activity. Various coactivators and transactivating sequences have been identified that may be required for steroid receptor transcriptional activity and discrimination between agonist-and antagonist-activated receptors in specific cell types (43) . Antiestrogens may also operate by other cellular mechanisms induding antagonism of calmodulin-regulated processes (42) to which steroid receptor reporter gene systems are likely to be insensitive. Assays with the potential to detect antiestrogens are of particular value because they may be important in evaluating certain classes of compounds such as the phytoestrogens and dioxins, which may have antiestrogenic activity and provide chemoprevention of certain cancers (38, 44) .
In vivo bioassays for estrogenic activity are of particular value because they provide a means of confirming the potential biological significance of in vitro findings (36) . The uterotrophic assay used in the present study produced estrogenic potencies that were relatively imprecise because only three doses of test compound were assayed. Nonetheless, with the exception of diethystilbestrol, lower potency values were derived using the uterotrophic assay compared with the recombinant yeast cell assay. Moreover, several compounds that have estrogenic activity in vitro, induding the phthalates, 4-octylphenol, and bisphenol A, had no detectable uterotrophic activity. Histological evaluation of vagina sections enabled further confirmation of estrogenic activity, as in all cases, uterotrophic activity was associated with cornification and thickening of the stratified squamous epithelium. Clearly, the biological significance of very weak estrogens detected with highly sensitive in vitro bioassays requires careful evaluation if activity in vivo is absent or found only at very high doses, which may exceed those giving rise to acute in vivo toxicity. Pharmacokinetic parameters (adsorption, metabolism, tissue distribution, and excretion) may have a significant influence on estrogenic activity in vivo, which cannot be readily accounted for in in vitro assays. These and other inherent differences between the RCBA and the murine uterotrophic assay will produce different potency values as found for diethylstilbestrol and other chemicals shown in Table 2 . Chronic exposure in vivo may facilitate the bioaccumulation of pollutants and their metabolites and thereby give rise to estrogenic activity not evident in acute (3 day) uterotrophic studies. The current situation is further complicated by recent conflicting reports (45, 46) relating to the potential for substantial synergistic interactions between xenoestrogens.
Biotransformation of xenobiotics in vivo is usually part of a process of deactivation and elimination, but proestrogens (e.g., certain phytoestrogens and organochlorines) may undergo metabolic activation to potent estrogens in various body compartments.
Although the range of compounds tested for biotransformation in the RCBA was limited, these studies provide valuable information on the fate of test compounds in this type of system. The corollary to the absence of significant steroid and xenobiotic biotransformation by the recombinant yeast cells is that, in their present form, they could not be utilized for the detection of proestrogens. Proestrogen detection in vitro has been accomplished by co-incubation of metabolizing and estrogen detecting systems (28, 42 
